Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial.

Saved in:
Bibliographic Details
Title: Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial.
Authors: Wang D; Department of Pulmonary and Critical Care Medicine, the First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei, 230001, China., Fu B; Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230027, China., Peng Z; Drug Clinical Trail Institution, the First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230001, China., Yang D; Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430000, China., Han M; Department of Respiratory Medicine, the Second People's Hospital of Fuyang, Fuyang, 236000, China., Li M; Department of Respiratory Medicine, National Key Clinical Specialty, Branch of National Clinical Research Center for Respiratory Disease, Xiangya Hospital, Central South University, Xiangya Lung Cancer Center, Xiangya Hospital, Central South University, Hunan Provincial Clinical Research Center for Respiratory Diseases, Changsha, 410000, China., Yang Y; Intensive Care Unit, the First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei, 230001, China., Yang T; Intensive Care Unit, the First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei, 230001, China., Sun L; Lu'an People's Hospital Affiliated to Anhui Medical University, Lu'an, 237005, China., Li W; Department of Pulmonary and Critical Care Medicine, the First Affiliated Hospital of Bengbu Medical College, Clinical Research Center for Respiratory Disease (tumor) in Anhui Province, Bengbu, 233004, China., Shi W; Department of Respiratory Medicine, Anqing Hospital Affiliated to Anhui Medical University, Anqing, 246000, China., Yao X; The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210000, China., Ma Y; Department of Rheumatology and Immunology, the First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei, 230001, China., Xu F; Department of Pulmonary and Critical Care Medicine, the First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei, 230001, China., Wang X; Department of Pulmonary and Critical Care Medicine, the First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei, 230001, China., Chen J; Department of Pulmonary and Critical Care Medicine, the First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei, 230001, China., Xia D; Department of Pulmonary and Critical Care Medicine, the First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei, 230001, China., Sun Y; Department of Oncology, the First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei, 230001, China., Dong L; Department of Endocrinology, the First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei, 230001, China., Wang J; Department of Endocrinology, the First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei, 230001, China., Zhu X; Department of Hematology, the First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei, 230001, China., Zhang M; Department of Rheumatology and Immunology, the First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei, 230001, China., Zhou Y; Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230027, China., Pan A; Intensive Care Unit, the First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei, 230001, China., Hu X; Department of Pulmonary and Critical Care Medicine, the First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei, 230001, China., Mei X; Department of Pulmonary and Critical Care Medicine, the First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei, 230001, China. hfmxd@sina.com., Wei H; Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230027, China. ustcwhm@ustc.edu.cn., Xu X; Department of Pulmonary and Critical Care Medicine, the First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei, 230001, China. xxlahh8@ustc.edu.cn.
Source: Frontiers of medicine [Front Med] 2021 Jun; Vol. 15 (3), pp. 486-494. Date of Electronic Publication: 2021 Mar 09.
Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial
Journal Info: Publisher: Higher Education Press Country of Publication: China NLM ID: 101549428 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2095-0225 (Electronic) Linking ISSN: 20950217 NLM ISO Abbreviation: Front Med Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2095-0225
DOI:10.1007/s11684-020-0824-3